Blindness secondary to prostate cancer.
We report a case of blindness, secondary to hormone-refractory prostate cancer, occurring 7 years after the diagnosis of metastatic prostate cancer and 3.5 years after the clinical onset of the hormone-refractory state. Prolonged suppression of the disease with chemotherapy may have contributed to the unusual clinical findings. We discuss the role of supportive care in the management of prostate cancer.
Vogelzang
N J
NJ
Department of Medicine, University of Chicago Hospitals, IL 60637-1470.
Olson
D
D
Chodak
G W
GW
D000230:Adenocarcinoma / Q000556:secondary*; D001766:Blindness / Q000209:etiology*; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary*; D003390:Cranial Nerve Neoplasms / Q000556:secondary*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009778:Occipital Lobe; D009897:Optic Chiasm; D011471:Prostatic Neoplasms / Q000150:complications*